Zoetis Inc.
Zoetis Reports Q4 2024 Results and Provides 2025 Guidance
Summary
Zoetis Inc. reported its financial results for the fourth quarter and full year 2024, highlighting a 5% increase in Q4 revenue to $2.3 billion and an 11% rise in Q4 net income to $581 million, or $1.29 per diluted share. For the full year, revenue grew by 8% to $9.3 billion, and net income increased by 6% to $2.5 billion, or $5.47 per diluted share. The company also provided its guidance for full year 2025, expecting revenue between $9.225 billion and $9.375 billion and adjusted diluted EPS between $6.00 and $6.10.
Profitelligence Alerts
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents
Advertisement